Message #25 From:
Stock News Bot Date: October 27, 2006 04:30:00 AM
STEM News StemCells, Inc. to Present at The Rodman & Renshaw 8th Annual Healthcare Conference
PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) today announced that Rodney Young, Chief
Financial Officer, will present a corporate update at the Rodman &
Renshaw 8th Annual Healthcare
Conference scheduled for November 6-8, 2006 at the New York Palace
Hotel in New York City. Mr. Young is scheduled to speak at 11:40 a.m.
EST on Tuesday, November 7, 2006. There will be a breakout session
following the presentation at which Mr. Young will be available to
answer questions about the Company.
A webcast of the presentation can be accessed via the following link: http://www.wsw.com/webcast/rrshq10/stem/.
The replay of the webcast will be available for 90 days following the
presentation.
About StemCells, Inc.
StemCells, Inc. is a clinical-stage biotechnology company leading the
discovery, development and commercialization of cell-based therapeutics
to treat diseases of the nervous system, liver and pancreas. The Company’s
programs seek to repair or repopulate neural or other tissue that has
been damaged or lost as a result of disease or injury. StemCells is the
first company to identify, isolate and purify human neural stem cells
from brain tissue. The Company is currently conducting a Phase I
clinical trial of its proprietary human neural stem cells (HuCNS-SC™)
for the treatment of infantile and late infantile neuronal ceroid
lipofuscinosis (NCL). NCL, which is often referred to as Batten disease,
is a rare and fatal neurodegenerative condition affecting infants and
young children. StemCells has approximately 40 U.S. and 100 non-U.S.
patents. Further information about the Company is available on its web
site at: www.stemcellsinc.com.
Apart from statements of historical facts, the text of this press
release constitutes forward-looking statements regarding, among other
things, the future business operations of StemCells, Inc. (the “Company”)
and its ability to conduct clinical trials as well as its research and
product development efforts. The forward-looking statements speak only
as of the date of this news release. StemCells does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof.Such statements
reflect management’s current views and are
based on certain assumptions that may or may not ultimately prove valid.
The Company’s actual results may vary
materially from those contemplated in the forward-looking statements due
to risks and uncertainties to which the Company is subject, including
uncertainty whether results obtained in the animal models of infantile
NCL will be able to be translated into treatment for humans; uncertainty
as to whether the FDA or other applicable regulators or review boards
will permit the Company to continue clinical testing in NCL despite the
novel and unproven nature of the Company’s
technology; uncertainties regarding the timing and duration of any
clinical trials; uncertainties regarding the Company’s
ability to obtain the increased capital resources needed to conduct the
later-phase clinical trials necessary for regulatory approvals of
HuCNS-SC; uncertainty regarding the validity and enforceability of the
Company’s patents; uncertainty as to whether
HuCNS-SC and any products that may be generated in the future in the
Company’s stem cell programs will prove safe
and clinically effective and not cause tumors or other side effects;
uncertainty as to whether the Company will achieve revenues from product
sales or become profitable; and other factors that are described under
the heading “Risk Factors”
in Item 1A of the Company’s Annual Report on
Form 10-K.
